The APOE ε4 allele was more common in participants with A+/T−/N−, A+/T−/N+, and A+/T+/N+; AR-AD and preclinical AD according to Dubois 2016 criteria; stage1 and stage 2 according to NIA-AA criteria; and asymptomatic at risk for Alzheimer disease according to the IWG-criteria (tables 3–5). This evidence concerns the gene APOE and Alzheimer disease.